Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies

Area of Science:

• Oncology
• Immunology
• Neuro-oncology

Background:

• Intracranial metastases are frequent in non-small-cell lung cancer (NSCLC), leading to a poor prognosis.
• Central nervous system (CNS) penetration challenges limit systemic treatments, and the CNS effects of immunotherapies are not well understood.

Purpose of the Study:

• To compare the frequency of intracranial progression in advanced NSCLC patients treated with PD-1 blockade versus those without.
• To investigate the efficacy of PD-1 blockade in preventing intracranial tumor recurrence and its impact on T-cell responses within the CNS.

Main Methods:

• Analysis of clinical data from advanced NSCLC patients comparing PD-1 blockade therapy with cytotoxic chemotherapy.
• Evaluation of intracranial tumor suppression and T-cell responses in murine models after PD-1 blockade treatment and tumor rechallenge.

Main Results:

• PD-1 blockade therapy was associated with a significantly lower frequency of intracranial progression compared to cytotoxic chemotherapies in advanced NSCLC.
• Murine models demonstrated suppression of rechallenged intracranial tumors post-PD-1 blockade, with increased memory T cells in lesions.
• Rechallenge with different tumors indicated that PD-1 blockade's efficacy might be antigen-specific.

Conclusions:

• Cancer immunotherapies, specifically PD-1 blockade, can effectively prevent intracranial progression and maintain long-term CNS and systemic anti-tumor effects.
• Aggressive local therapies may be beneficial if intracranial recurrence occurs during PD-1 blockade treatment.